Efanesoctocog Alfa Versus Emicizumab in Adolescent and Adult Patients With Haemophilia A Without Inhibitors.

Adv Ther · 2025 · PMC11782328 · PMID 39576432

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Lower rates of other bleed types were also observed with efanesoctocog alfa versus emicizumab; however, these did not reach statistical significance, including any treated bleeds, treated spontaneous bleeds, and treated joint bleeds.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.